Physician profile
Nailesh Dave
NPI 1184680522
$9,262.49
in general payments reported to CMS, 2019-2025
57 companies · $1,395 in 2025
The $1,395 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,326 · 2020: $1,342 · 2021: $875 · 2022: $956 · 2023: $929 · 2024: $1,440 · 2025: $1,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,561 · Education: $188 · Travel and Lodging: $15.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,560.73 |
| Education | $188.00 |
| Travel and Lodging | $15.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,326.03 | 2019-2025 | Proclaim, Eterna |
| Novartis Pharmaceuticals Corporation | $1,257.73 | 2019-2025 | |
| Amgen INC. | $628.99 | 2019-2022 | |
| Nevro Corp. | $592.65 | 2022-2024 | Senza |
| Jazz Pharmaceuticals INC. | $589.19 | 2019-2025 | Xywav |
| Supernus Pharmaceuticals, INC. | $530.44 | 2019-2020 | |
| Allergan, INC. | $331.29 | 2019-2021 | |
| Biogen, INC. | $260.49 | 2019-2025 | Vumerity, Avonex, Plegridy |
| Scilex Pharmaceuticals INC. | $237.31 | 2021-2025 | |
| Livanova USA, INC. | $228.89 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Neurocrine Biosciences, INC. | $223.16 | 2024-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $175.12 | 2019-2023 | Austedo Xr |
| Neurelis, INC. | $173.32 | 2021-2025 | Valtoco |
| Ucb, INC. | $171.65 | 2019-2025 | Briviact |
| Emd Serono, INC. | $170.47 | 2019-2022 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nailesh Dave listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.